Clinical oversight remains essential: dosing protocols, treatment duration, and patient monitoring should follow established peptide therapy guidelines
This helps ensure that any potential issues can be addressed promptly
In contrast, short-acting formulations such as exenatide and the older-generation agent lixisenatide are now prescribed far less frequently, and several formulations have been withdrawn from the market in certain countries, largely due to limited clinical uptake, the availability of more effective long-acting alternatives, and commercial considerations rather than confirmed safety concerns
Potential improvements in cholesterol levels have been noted
Activating both at the same time produces a substantially larger pulse more than the sum of the two individual effects
doi: 10.1038/sj.cdd.4401271 177 ZouBLiuXYuHZhangSXiePSunBet al